The sale is de minimis and carries no material signal. Monitor for any larger insider sales or changes in director holdings in future Form 4 filings.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 2 $145.35entry
- T+1 · 14d ago +13.42%α +13.12% · $164.85
- T+5 · 8d ago +16.17%α +16.10% · $168.86
- T+10 · todayOpen
- T+20 · in 14d Pending
- T+60 · in 2mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director George J. Morrow filed a Form 144 notice of intent to sell 300 shares of Neurocrine Biosciences common stock, valued at approximately $43,914 based on the filing date. The shares were acquired through option exercise on the same date. The proposed sale is very small relative to the company's $14.8B market cap and represents a routine insider transaction.
Key Facts
- Director George J. Morrow filed Form 144 to sell 300 shares of NBIX common stock.
- Estimated value of proposed sale: $43,914 (based on filing date).
- Shares were acquired via option exercise on 10/30/2026.
- Sale is immaterial relative to NBIX's $14.8B market cap.
- Form 144 signals intent to sell; the sale may not occur.
Financial Impact
Proposed sale of 300 shares worth ~$43,914, less than 0.0003% of market cap.
Risk Factors
- Form 144 is only an intent to sell; the transaction may not be executed.
- No additional context on the insider's total holdings is provided in the filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010505 |
| Document: 0001950047-26-010505-index.html | 0001950047-26-010505 |
| Document: 0001950047-26-010505.txt | 0001950047-26-010505 |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Viewing Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers